ERBB2 and neoplasm: Interestingly, the bispecific liposomes delivered the encapsulated DY676-COOH into the nuclei of the tumor cells similar to trastuzumab-based liposomes in previous reports [22], which indicates that the encapsulation of “nuclei active” therapeutic drugs within the bispecific liposomes also has potential to manage drug resistance in patients with high HER2 expressing tumors in the future.